www.medical-devices.tech
20
'25
Written on Modified on
Alcon Announces U.S. Launch of Voyager DSLT
Voyager DSLT is designed to automatically deliver 120 laser pulses directly through the limbus to the trabecular meshwork to improve aqueous outflow and reduce intraocular pressure.
Alcon announced the full U.S. commercial availability of Voyager™ DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment’s availability for more patients. Designed for an exceptional patient and physician experience, Voyager DSLT is fully automated—efficiently delivering 120 laser pulses without the need for a gonio lens as with manual SLT. Attendees of the 2025 American Glaucoma Society (AGS) meeting in Washington, D.C., from February 26 through March 2, will be able to experience Voyager DSLT first-hand at the Alcon booth (#29-32) and during the launch event.
Glaucoma is a progressive disease that impacts millions of people around the world. In the U.S. alone, the number of glaucoma patients is expected to grow from 5 million to 6.3 million by 2050. Glaucoma is the leading cause of irreversible blindness globally, with many unaware that they have glaucoma until the disease has progressed to vision loss. Due to its progressive nature, early intervention and a variety of treatment options—from drops to surgical intervention—is critical to preserve sight.
Voyager DSLT is controlled through an intuitive touchscreen, taking the slit lamp and manual gonio lens aiming out of the equation, and reduces the specialized training required with manual SLT. Voyager DSLT offers precise delivery, powered by SureTrac™ eye-tracking technology, to accurately and safely deliver laser pulses through the limbus to the trabecular meshwork, stimulating the eye's natural healing response to improve aqueous outflow. Additionally, in a survey of 24 physicians who experienced a DSLT demo, 96% agreed they would want to be offered first-line DSLT if they were patients.
A randomized, controlled trial has shown that DSLT delivers effective intraocular pressure (IOP) control and has a strong safety profile with low risk of adverse events. The data and early feedback demonstrate:
- Nearly 2 out of 3 (62%) DSLT participants were medication-free at 12 months.
- After 6 months, nearly all DSLT patients indicated they would recommend the treatment to a friend with glaucoma.
- The benefits of DSLT position laser therapy to become a more widespread first-line intervention for glaucoma patients.
For more information on Voyager DSLT, please visit our website.
